Asia Pacific Contraceptives Market size crossed USD 6.6 billion in 2021 and is projected to exhibit a CAGR of 10.2% between 2022 and 2028. The increasing prevalence of STDs and STIs in Asia Pacific region is projected to fuel the market demand.

Get more details on this report - Request Free Sample PDF

Adoption of supportive initiatives by government authorities along with public organizations is expected to drive the adoption of contraceptives. These initiatives aid in prevention of STDs and STIs, targeting those at greatest risk and are crucial to curb the spread of HIV. For instance, the Challenge Initiative (TCI) is a demand-based, family planning tool that is used for sustainable scale and impact that enables governments to lead family planning implementation. This tool is currently active in several developing countries, including certain countries in Asia.

Asia Pacific Contraceptives Market, By Product

The devices segment revenue will cross USD 11,401 million by 2028, due to the rise in the reproductive population and surging prevalence of STIs in the region. Owing to high reproductive population, certain countries in the region are amongst the highest users of contraceptives.

According to the United Nations’ 2019 report, in countries such as India, Japan, South Korea, Indonesia, and other, more than 50% of the females of reproductive age (aged 15-49 years) use contraceptives. China and Japan are amongst the highest users of contraceptive devices including male condoms accounting for more than 20% of the overall use of contraceptives. In addition to this, the increasing prevalence of STDs in the region is further set to promote the demand for contraceptives.

Asia Pacific Market, By Country

China contraceptives market accounted for 29.6% revenue share in 2021 and will exceed USD 4,310 million revenue by 2028, attributed to the increasing prevalence of STDs and surged use of contraceptives in the country. Acquired immunodeficiency syndrome (AIDS) pertaining to HIV infection, gonorrhoea, and syphilis are the three commonly prevalent STDs in the country.

As per the Law of the Peoples’ Republic of China on Prevention and Control of Infectious Diseases, diagnosed STDs are required to be reported to national surveillance systems. The surveillance systems reported that in 2019, there were 50,874 new cases of genital chlamydial infection, corresponding to 55.32, every 100,000 individuals. This estimate further highlights a 9.98% increase as compared to 2018. Moreover, the highest incidence rate of this infection ranges from 137.49–233.37 cases, every 100,000 individuals.

Competitive Industry Landscape

Major players involved in the Asia Pacific contraceptives market are Allergan Plc, Bayer Corporation, Cooper Surgical, Inc., Church & Dwight Co., Inc., Mayer Laboratories, Inc., Merck & Co. Inc., Pfizer, Reckitt Benckiser Group Plc, and Teva Pharmaceuticals Industries Ltd.

These companies are implementing several organic and inorganic strategies such as product launches and partnerships for garnering maximum market share and strengthening their industrial presence.